A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT04845139
Status
Unknown

Conditions

  • Primary Central Nervous System Lymphoma
  • Refractory Central Nervous System Lymphoma
  • Relapsed Primary Central Nervous System Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab given intraventricularly

Study Details

The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Key Dates

Start date
Jul 2, 2022
Status verified
Jul 2022
Primary completion
Oct 30, 2022
Completion
Nov 30, 2022

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab administration
    Nivolumab administration Q2W by intraventricular injection through Ommaya reservoir

Primary Outcome Measure

Adverse events [ Time Frame: On a continuous basis up to 1 month after the first dose of study drug ]

Related Studies